- Home
- FCAP vs OTLK Comparison
FCAP vs OTLK Comparison
Compare FCAP & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FCAP | OTLK |
|---|---|---|
| Founded | 1891 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.7M | 249.6M |
| IPO Year | 1998 | 2016 |
Fundamental Metrics
Financial Performance| Metric | FCAP | OTLK |
|---|---|---|
| Price | $61.61 | $0.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.03 |
| AVG Volume (30 Days) | 14.3K | ★ 3.4M |
| Earning Date | 10-23-2026 | 08-14-2026 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | 36.97 | ★ 55.91 |
| EPS | ★ 2.72 | N/A |
| Revenue | $7,170,000.00 | ★ $8,146,123.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6,355.64 |
| P/E Ratio | $22.68 | ★ N/A |
| Revenue Growth | ★ 1.57 | N/A |
| 52 Week Low | $37.64 | $0.16 |
| 52 Week High | $71.00 | $2.54 |
Technical Indicators
Market Signals| Indicator | FCAP | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 48.22 | 31.66 |
| Support Level | $59.91 | $0.50 |
| Resistance Level | $64.23 | $0.72 |
| Average True Range (ATR) | 1.86 | 0.04 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 67.54 | 0.06 |
Price Performance
Historical ComparisonAbout FCAP First Capital Inc.
First Capital Inc is an Indiana chartered commercial bank that provides a variety of banking services to individuals and businesses. It provides retail and business banking, residential mortgage lending, real estate finance, and asset-based lending. The bank's primary source of revenue is real estate mortgage loans.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.